期刊文献+
共找到120篇文章
< 1 2 6 >
每页显示 20 50 100
Live births from in vitro fertilization-embryo transfer following the administration of gonadotropin-releasing hormone agonist without gonadotropins:Two case reports
1
作者 Mai Li Ping Su Li-Ming Zhou 《World Journal of Clinical Cases》 SCIE 2023年第9期2067-2073,共7页
BACKGROUND The prevalence of female infertility between the ages of 25 and 44 is 3.5%to 16.7%in developed countries and 6.9%to 9.3%in developing countries.This means that infertility affects one in six couples and is ... BACKGROUND The prevalence of female infertility between the ages of 25 and 44 is 3.5%to 16.7%in developed countries and 6.9%to 9.3%in developing countries.This means that infertility affects one in six couples and is recognized by the World Health Organization as the fifth most serious global disability.The International Committee for Monitoring Assisted Reproductive Technology reported that the global total of babies born as a result of assisted reproductive technology procedures and other advanced fertility treatments is more than 8 million.Advancements in controlled ovarian hyperstimulation procedures led to crucial accomplishments in human fertility treatments.The European Society for Human Reproduction and Embryology guideline on ovarian stimulation gave us valuable evidence-based recommendations to optimize ovarian stimulation in assisted reproductive technology.Conventional ovarian stimulation protocols for in vitro fertilization(IVF)–embryo transfer are based upon the administration of gonadotropins combined with gonadotropin-releasing hormone(GnRH)analogues,either GnRH agonists(GnRHa)or antagonists.The development of ovarian cysts requires the combination of GnRHa and gonadotropins for controlled ovarian hyperstimulation.However,in rare cases patients may develop an ovarian hyper response after administration of GnRHa alone.CASE SUMMARY Here,two case studies were conducted.In the first case,a 33-year-old female diagnosed with polycystic ovary syndrome presented for her first IVF cycle at our reproductive center.Fourteen days after triptorelin acetate was administrated(day 18 of her menstrual cycle),bilateral ovaries presented polycystic manifestations.The patient was given 5000 IU of human chorionic gonadotropin.Twenty-two oocytes were obtained,and eight embryos formed.Two blastospheres were transferred in the frozen-thawed embryo transfer cycle,and the patient was impregnated.In the second case,a 37-year-old woman presented to the reproductive center for her first donor IVF cycle.Fourteen days after GnRHa administration,the transvaginal ultrasound revealed six follicles measuring 17-26 mm in the bilateral ovaries.The patient was given 10000 IU of human chorionic gonadotropin.Three oocytes were obtained,and three embryos formed.Two high-grade embryos were transferred in the frozen-thawed embryo transfer cycle,and the patient was impregnated.CONCLUSION These two special cases provide valuable knowledge through our experience.We hypothesize that oocyte retrieval can be an alternative to cycle cancellation in these conditions.Considering the high progesterone level in most cases of this situation,we advocate freezing embryos after oocyte retrieval rather than fresh embryo transfer. 展开更多
关键词 gonadotropin-releasing hormone agonist Ovarian hyperstimulation In vitro fertilization Live birth INFERTILITY Frozen-thawed embryo transfer Human chorionic gonadotropin Case report
下载PDF
Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
2
作者 Hee Jun Choi Jun Ho Lee +9 位作者 Chang Shin Jung Jai Min Ryu Byung Joo Chae Se Kyung Lee Jong Han Yu Seok Won Kim Seok Jin Nam Jeong Eon Lee Youn Joo Jung Hyun Yul Kim 《World Journal of Clinical Cases》 SCIE 2023年第27期6398-6406,共9页
BACKGROUND Breast cancer in young women has been shown to have an aggressive behavior and poor prognosis.AIM To evaluate the outcomes of young hormone receptor(HR)-positive patients with breast cancer treated with neo... BACKGROUND Breast cancer in young women has been shown to have an aggressive behavior and poor prognosis.AIM To evaluate the outcomes of young hormone receptor(HR)-positive patients with breast cancer treated with neoadjuvant chemotherapy(NAC),and the oncologic efficacy of gonadotropin-releasing hormone(GnRH)agonists.METHODS This retrospective study involved a prospectively enrolled cohort.We included patients diagnosed with invasive breast cancer who were treated with NAC followed by curative surgery at the Samsung Medical Center and Samsung Changwon Hospital between January 2006 and December 2017.Among patients with HR-positive and human epidermal grow factor 2(HER2)-negative breast cancer,we analyzed the characteristics and oncology outcomes between the patients equal to or younger than 35 years and the patients older than 35 years.RESULTS Among 431 patients with NAC and HR-positive/HER2-negative breast cancer,78 were 35 years old or younger,and 353 patients were older than 35 years.The median follow-up was 71.0 months.There was no statistically significant difference in disease free survival(DFS,P=0.565)and overall survival(P=0.820)between the patients equal to or younger than 35 years and the patients older than 35 years.The two groups differed in that the GnRH agonist was used more frequently in the group of patients equal to or younger than 35 years than in the other group(52.4%vs 11.2%,P<0.001).Interestingly,for the DFS according to the GnRH agonist in the group of patients equal to or younger than 35 years,patients treated with the GnRH agonist had better DFS(P=0.037).CONCLUSION Administration of GnRH agonists might improve the DFS rate of HR-positive/HER2-negative breast cancer in the equal to or younger than 35 years group of patients with NAC. 展开更多
关键词 gonadotropin-releasing hormone Agonist YOUNG BREAST CANCER
下载PDF
Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer 被引量:7
3
作者 Li WU Xin-ling REN +3 位作者 Wen CHEN Bo HUANG Yi-fan ZHOU Lei JIN 《Current Medical Science》 SCIE CAS 2019年第3期437-441,共5页
This study aimed to investigate the effect of different gonadotropin-releasing hormone agonist (GnRH-a) administration methods on pregnancy outcomes of patients undergoing in-vitro fertilization-embryo transfer (IVF-E... This study aimed to investigate the effect of different gonadotropin-releasing hormone agonist (GnRH-a) administration methods on pregnancy outcomes of patients undergoing in-vitro fertilization-embryo transfer (IVF-ET). Clinical data of 5217 patients who underwent IVF-ET were retrospectively analyzed. Patients were divided into the long-acting GnRH-a group (n=1330) and the short-acting GnRH-a group (w=3887) based on their various treatment plans. The clinical and laboratory embryo data and clinical pregnancy outcomes were compared between the two groups. The results showed that there were no significant differences in the age, infertility, primary/secondary infertility rate, IVF rate, body mass index (BMI), antral follicle counting (AFC), folliclestimulating hormone (FSH) level, and the number of transplanted embryos between the two groups (P>0.05). There were no significant differences in the oocyte numbers, M II rate, fertilization rate, cleavage rate and blastocyst formation rate (P>0.05) between the two groups. The gonadotropin (Gn) using days, Gn dose and endometrial thickness were significantly greater in the long-acting GnRH-a group than those in the short-acting GnRH-a group (P<0.01). Additionally, the estradiol (E2) levels, blastocyst freezing rate, embryo utilization rate, transplant cancellation rate and abortion rate were significantly lower in the long-acting GnRH-a group than those in the shortacting GnRH-a group (P<0.01). The clinical pregnancy rate and embryo implantation rate were significantly higher in the long-acting GnRH-a group than in the short-acting GnRH-a group (P<O.Ol). It was concluded that use of long-acting GnRH-a can effectively reduce the transplant cancellation rate and improve the clinical pregnancy rate of the fresh cycle. 展开更多
关键词 gonadotropin-releasing hormone AGONIST LONG-ACTING short-acting in-vitro fertilization-embryo transfer clinical pregnancy rate
下载PDF
Changes in Electrocardiogram Findings during Treatment with Gonadotropin-Releasing Hormone Agonist and Surgical Castration for Prostate Carcinoma
4
作者 Hasan Saglam Akif Cakar +4 位作者 Osman Kose Sukru Kumsar Salih Budak Serbulent Gokhan Beyaz Oztug Adsan 《Open Journal of Urology》 2012年第3期153-156,共4页
Purpose: To investigate electrocardiogram (ECG) changes after complete androgen blockade (CAB) achieved by either surgical or medical castration and compare the outcomes of the groups. Methods: Sixty-three consecutive... Purpose: To investigate electrocardiogram (ECG) changes after complete androgen blockade (CAB) achieved by either surgical or medical castration and compare the outcomes of the groups. Methods: Sixty-three consecutive men (between 58 - 86 years of age) requiring CAB for prostate cancer were enrolled in the study. Patients with diabetes mellitus, an additional malignancy, coronary heart disease, atrial fibrillation, heart failure or a medical history of cardiac event in the last 12 months were excluded from the study. Additionally, those who were taking medicine affecting heart rate were excluded. The participants were divided into two groups according to their modality of castration. The first group consisted of 35 patients who received bilateral orchiectomy plus anti-androgen medication. The second group contained 28 patients who accepted gonadotropin-releasing hormone (GnRH) plus anti-androgen therapy. After complete examinations and biochemical tests, the ECG leads of the patients were obtained conveniently. This was then repeated at three- and six-month visits. ECG findings (including heart rate, PR, QRS, QT, corrected QT (QTc) intervals and QT dispersion (QTd)) were recorded and analysed statistically. The groups were then compared in terms of pre- and post-treatment ECG outcomes. Results: Both groups revealed similarly lower heart rate and prolonged PR, QRS, QT, corrected QTc and QTd by the end of six months. By the end of three months, all variables had changed significantly in the orchiectomy group, whereas in the GnRH group, they had not. Conclusion: CAB may result in lower heart rate and prolonged QT, a condition associated with fatal cardiac arrhythmia and sudden death. Therefore, patients receiving CAB should be monitored closely for cardiac adverse effects. 展开更多
关键词 gonadotropin-releasing hormone CASTRATION TESTOSTERONE ELECTROCARDIOGRAM QT Interval Heart Rate
下载PDF
Interactions of Sex Steroids with Gonadotropin-Releasing Hormone in the Regulation of Gonadotropin (GtH) and Growth Hormone (GH) Release in the Common Carp (Cyprinus Carpio)
5
作者 H.R.Lin M.Lu +2 位作者 W.M.Zhang X.W.Lin L.X.Chen 《中山大学学报论丛》 1995年第3期220-222,共3页
关键词 GtH GH Interactions of Sex Steroids with gonadotropin-releasing hormone in the Regulation of Gonadotropin Cyprinus Carpio Release in the Common Carp and Growth hormone
下载PDF
Regulation of Gonadotropin-Releasing Hormone(GnRH)Secretion and mRNA Expression by Dopamine and cAMP Second Messenger Pathway in a GnRH Neuronal Cell Line
6
作者 K.L.Yu M.H.Tsang K.W.Dong 《中山大学学报论丛》 1995年第3期197-197,共1页
关键词 GnRH)Secretion and mRNA Expression by Dopamine and cAMP Second Messenger Pathway in a GnRH Neuronal Cell Line Regulation of gonadotropin-releasing hormone
下载PDF
青春期矮身材儿童身高改善的药物治疗
7
作者 朱建芳 王春林 《中国当代儿科杂志》 CAS CSCD 北大核心 2024年第2期118-123,共6页
青春期矮身材可严重影响青少年的身心健康。青春期由于性激素导致的骨龄持续加速进展,限制了生长所需的时间,是矮身材治疗的巨大挑战,至今仍无标准化的治疗方案。青春期也是改善成年终身高的最后机会。目前临床常用治疗药物主要有重组... 青春期矮身材可严重影响青少年的身心健康。青春期由于性激素导致的骨龄持续加速进展,限制了生长所需的时间,是矮身材治疗的巨大挑战,至今仍无标准化的治疗方案。青春期也是改善成年终身高的最后机会。目前临床常用治疗药物主要有重组人生长激素、促性腺激素释放激素类似物和第三代芳香化酶抑制剂。近年来,以改善成年终身高为目的的个体化治疗成为临床关注的重点。该文对青春期矮身材儿童身高改善的药物治疗相关研究进行梳理总结,为临床医生提供参考. 展开更多
关键词 矮身材 重组人生长激素 促性腺激素释放激素类似物 芳香化酶抑制剂 青春期
下载PDF
关于改善中枢性性早熟患儿身高获益的思考
8
作者 梁立阳 《中国当代儿科杂志》 CSCD 北大核心 2024年第1期19-24,共6页
随着遗传和环境等多种因素的改变,儿童性早熟的发病率逐渐增加,以改善身高为目的的性早熟治疗是临床关注的重点问题之一。目前,促性腺激素释放激素类似物(gonadotropin-releasing hormone analogs,GnRHa)仍是首选治疗药物,但其对身高的... 随着遗传和环境等多种因素的改变,儿童性早熟的发病率逐渐增加,以改善身高为目的的性早熟治疗是临床关注的重点问题之一。目前,促性腺激素释放激素类似物(gonadotropin-releasing hormone analogs,GnRHa)仍是首选治疗药物,但其对身高的改善作用受多种因素影响,可能导致身高获益低于预期。联合重组人生长激素(recombinant human growth hormone,rhGH)治疗是提高GnRHa疗效的可选治疗策略,然而联用时机等尚无明确推荐。基于性早熟治疗现状,重新审视单用GnRHa及联合rhGH治疗对身高的改善作用至关重要。该文探索了联合治疗适应证等策略,以期指导临床用药,帮助性早熟患儿实现更理想的身高获益。 展开更多
关键词 性早熟 身高获益 促性腺激素释放激素类似物 生长激素 儿童
下载PDF
Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism 被引量:3
9
作者 Ying Liu Xiao-Ya Ren +7 位作者 Ya-Guang Peng Shao-Ke Chen Xin-Ran Cheng Miao Qin Xiao-Ling Wang Yan-Ning Song Li-Jun Fan Chun-Xiu Gong 《Chinese Medical Journal》 SCIE CAS CSCD 2021年第10期1152-1159,共8页
Background:Compared to adult studies,studies which involve the treatment of pediatric congenital hypogonadotropic hypogonadism(CHH)are limited and no universal treatment regimen is available.The aim of this study was ... Background:Compared to adult studies,studies which involve the treatment of pediatric congenital hypogonadotropic hypogonadism(CHH)are limited and no universal treatment regimen is available.The aim of this study was to evaluate the feasibility of human chorionic gonadotropin(hCG)/human menopausal gonadotropin(hMG)therapy for treating male adolescents with CHH.Methods:Male adolescent CHH patients were treated with hCG/hMG(n=20)or a gonadotropin-releasing hormone(GnRH)pump(n=21).The treatment was divided into a study phase(0-3 months)and a follow-up phase(3-12 months).The testicular volume(TV),penile length(PL),penis diameter(PD),and sex hormone levels were compared between the two groups.The TV and other indicators between the groups were analyzed using a t-test(equal variance)or a rank sum test(unequal variance).Results:Before treatment,there was no statistical difference between the two groups in terms of the biochemistry,hormones,and other demographic indicators.After 3 months of treatment,the TV of the hCG/hMG and GnRH groups increased to 5.1±2.3 mL and 4.1±1.8 mL,respectively;however,the difference was not statistically significant(P>0.05,t=1.394).The PL reached 6.9±1.8 cm and 5.1±1.6 cm(P<0.05,t=3.083),the PD reached 2.4±0.5 cm and 2.0±0.6 cm(P<0.05,t=2.224),respectively,in the two groups.At the end of 6 months of treatment,biomarkers were in normal range in the two groups.Compared with the GnRH group,the testosterone(T)level and growth of PL and PD were significantly greater in the hCG/hMG group(all P<0.05).While the TV of both groups increased,the difference was not statistically significant(P>0.05,t=0.314).After 9 to 12 months of treatment,the T level was higher in the hCG/hMG group.Other parameters did not exhibit a statistical difference.Conclusions:The hCG/hMG regimen is feasible and effective for treating male adolescents with CHH.The initial 3 months of treatment may be a window to optimally observe the strongest effects of therapy.Furthermore,results from the extended time-period showed positive outcomes at the 1-year mark;however,the long-term effectiveness,strengths,and weaknesses of the hCG/hMG regimen require further research.Trial Registration:ClinicalTrials.gov,NCT02880280;https://clinicaltrials.gov/ct2/show/NCT02880280. 展开更多
关键词 Congenital hypogonadotropic hypogonadism gonadotropin-releasing hormone Human chorionic gonadotropin Human menopausal gonadotropin Treatment regime
原文传递
Treatment of central precocious puberty by GnRH analogs: long-term outcome in men 被引量:13
10
作者 Silvano Bertelloni Dick Mul 《Asian Journal of Andrology》 SCIE CAS CSCD 2008年第4期525-534,共10页
在男孩,中央早熟的发身(CPP ) 是以前垂体促性腺激素分泌物驾驶的第二等的性别特征的外观 9 年的年龄。在最后年里,在 CPP 的处理的相关改进被完成了。因为 CPP 在男孩是稀罕的,这个问题上的报纸的多数集中于女孩并且不关于结束结果... 在男孩,中央早熟的发身(CPP ) 是以前垂体促性腺激素分泌物驾驶的第二等的性别特征的外观 9 年的年龄。在最后年里,在 CPP 的处理的相关改进被完成了。因为 CPP 在男孩是稀罕的,这个问题上的报纸的多数集中于女孩并且不关于结束结果和安全探讨男病人的特定的特征。在现在的纸,有在男人的 GnRH 类似物的 CPP 管理的最近的进展被总结。在未经治疗、对待的病人的结束结果被最近出版的文学的分析也在男人在 CPP 的治疗上考察。可得到的数据显示没有重要不利短期、长期的效果,有 GnRH 类似物的那治疗能改进最后的高度进目标高度的范围,但是病人的更大的系列的更长的后续是仍然要求了得出权威的结论。 展开更多
关键词 男性 青少年 青春期早熟 治疗 GNRH
下载PDF
Studying the nature of ascending-descending-floating-sinking of Chinese medicines based on gonadotropin-releasing hormone
11
作者 FU Yang YUAN Peipei +5 位作者 ZENG Mengnan HOU Ying GAO Liyuan WEI Yaxin ZHENG Xiaoke FENG Weisheng 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2022年第4期546-555,共10页
OBJECTIVE:To explore the nature of ascendingdescending-floating-sinking of Traditional Chinese Medicine on normal rats using gonadotropin-releasing hormone(GnRh).METHODS:Normal male Sprague-Dawley rats were orally adm... OBJECTIVE:To explore the nature of ascendingdescending-floating-sinking of Traditional Chinese Medicine on normal rats using gonadotropin-releasing hormone(GnRh).METHODS:Normal male Sprague-Dawley rats were orally administered six floating Chinese medicines and seven sinking Chinese medicines for 14 d.Then,GnRh and relevant indicators were detected.Initially,the different effects of floating and sinking drugs on the body were explored.To verify the effects of floating and sinking drugs on the body,normal rats were orally administered Mahuang(Herba Ephedra Sinica)and Tinglizi(Semen Lepidii Apetali)for 14 d.Then,GnRh antagonists were administered.We observed the changes of relevant indicators and clarified the correlation between GnRh and the laws of floating and sinking.RESULTS:Floating Chinese medicines significantly increased the testicular coefficients;GnRh level in the serum;the protein level of GnRh receptor(GnRhR)in the testis;and the mRNA levels of androgen receptor(AR),small C-terminal domain phosphatase(SCP)3,SCP2,SYCE1,SMC1 B,SMC3,and Rec8(P<0.01 or<0.05).Sinking Chinese medicines did not react similarly,while GnRh antagonists blocked the regulatory effect of Mahuang(Herba Ephedra Sinica)but did not affect Tinglizi(Semen Lepidii Apetali).CONCLUSIONS:GnRh may be closely related to the nature of ascending-descending-floating-sinking of Chinese medicine.Floating Chinese medicines may promote their medicinal properties by regulating Gn RH level;however,sinking Chinese medicines did not affect GnRh level. 展开更多
关键词 gonadotropin-releasing hormone receptors LHRH Mahuang(Herba Ephedra Sinica) Tinglizi(Semen Lepidii Apetali) testis ascending-descending-floating-sinking
原文传递
Effect of Guizhi Fuling Pill combined with GnRH analog on cell proliferation and invasion as well as MEK/ERK pathway in endometriosis lesions
12
作者 Li-Qiong Chen 《Journal of Hainan Medical University》 2017年第19期93-96,共4页
Objective: To study the effect of Guizhi Fuling Pill combined with gonadotropin-releasing hormone analog (GnRH-a) on cell proliferation and invasion as well as MEK/ERK pathway in endometriosis lesions. Methods: Patien... Objective: To study the effect of Guizhi Fuling Pill combined with gonadotropin-releasing hormone analog (GnRH-a) on cell proliferation and invasion as well as MEK/ERK pathway in endometriosis lesions. Methods: Patients who were diagnosed with endometriosis in Bazhong Hospital of Traditional Chinese Medicine between November 2014 and March 2017 were selected as the research subjects and randomly divided into two groups, observation group received preoperative Guizhi Fuling Pill combined with GnRH analog therapy, and control group received preoperative GnRH analog monotherapy. After surgical resection, the endometriosis lesion was collected to determine the mRNA expression of proliferation and invasion-related genes as well as the protein expression of MEK/ERK pathway molecules. Results: Id-1, Sema3A, c-IAP1, OPN and uPA mRNA expression as well as p-MEK, p-EKR1/2, caspase-3 and MMP2 protein expression in endometriosis lesion of observation group were significantly lower than those of control group while Bak, Smac, PAI-1, TIMP1 and TIMP2 mRNA expression as well as caspase-3 protein expression were significantly higher than those of control group. Conclusion: Guizhi Fuling Pill combined with GnRH analog can inhibit the cell proliferation and invasion as well as the MEK/ERK pathway activation in endometriosis lesions. 展开更多
关键词 ENDOMETRIOSIS gonadotropin-releasing hormone analog CELL proliferation CELL INVASION MEK/ERK signaling PATHWAY
下载PDF
促性腺激素释放激素(GnRH)类似物在辅助生殖治疗领域中的研究进展
13
作者 周郁恬 孟艳 +1 位作者 刁飞扬 刘金勇 《南京师大学报(自然科学版)》 CAS 北大核心 2023年第4期68-73,共6页
促性腺激素释放激素(GnRH)类似物主要包括GnRH激动剂(gonadotropin-releasing hormone agonist,GnRH-a)和GnRH拮抗剂(gonadotropin-releasing hormone antagonist,GnRH-A),在辅助生殖技术多个治疗环节均发挥着重要作用.近年来,针对不同... 促性腺激素释放激素(GnRH)类似物主要包括GnRH激动剂(gonadotropin-releasing hormone agonist,GnRH-a)和GnRH拮抗剂(gonadotropin-releasing hormone antagonist,GnRH-A),在辅助生殖技术多个治疗环节均发挥着重要作用.近年来,针对不同适宜人群进行的、基于GnRH的控制性卵巢刺激改良策略,在不同适宜人群中的使用显著提高了体外受精成功率.GnRH-a在扳机方案中使用的适宜人群选择及对临床结局的影响已在近年临床研究中有深入探讨.而GnRH-a在黄体支持方案中的使用,适宜人群的选择及使用剂量、时机仍需进一步探索.本文就GnRH类似物在辅助生殖领域中的应用机制及相关临床研究的最新进展进行回顾总结. 展开更多
关键词 促性腺激素释放激素类似物 辅助生殖 控制性卵巢刺激方案 扳机方案 黄体支持方案
下载PDF
Clinical efficacy of leprerelin acetate with different dosage forms in central precocious puberty girls
14
作者 YANG Ming-ming TANG Yong-quan +3 位作者 GAO Qian WANG Jie JIANG Xue ZHOU Wen-di 《Journal of Hainan Medical University》 CAS 2023年第22期32-38,共7页
Objective:To observe the clinical efficacy of different dosage forms of lepraline acetate(LA)in the treatment of girls with central precocious puberty(CPP).Methods:72 CPP girls treated in the Department of Pediatrics ... Objective:To observe the clinical efficacy of different dosage forms of lepraline acetate(LA)in the treatment of girls with central precocious puberty(CPP).Methods:72 CPP girls treated in the Department of Pediatrics of Huai'an First People's Hospital from February 2021 to August 2022 were included as subjects and divided into two groups:3-month LA group(n=34)and 1-month LA group(n=38).Both group girls were treated for 6 months.Serum hormone levels,body mass index(BMI),bone age/chronological age(BA/CA)and pelvic color ultrasound were detected at 0 and 6 months after treatment,and the changes of various indexes were compared before and after treatment.Results:1)There were no significant differences in baseline data between the two groups before treatment(P>0.05).2)After 6 months of treatment,BA/CA decreased,growth rate slowed down,and predicted adult height increased in both groups(P<0.05),but there were no significant differences between groups(P>0.05).3)After 6 months of treatment,there waere no significant differences in luteinizing hormone(LH)inhibition ratio between the 3 month and 1 month dosage groups(P>0.05).After treatment,the peak value of serum LH and FSH,estradiol level,uterine volume,bilateral ovarian volume,maximum follicle diameter and the number of follicles 4mm were significantly decreased in the two groups,but there were no significant differences between the two groups(P>0.05).4)There were no significant differences in the levels of thyroid hormone,fasting blood glucose and triglyceride between the two groups before and after treatment(P>0.05).Total cholesterol levels were increased after treatment(P<0.05),but there was no significant difference between groups(P>0.05).5)No serious adverse reactions occurred during the treatment of the two dosage forms of LA,but the 3-month dosage form of LA reduced the treatment cost and improved the treatment compliance.Conclusion:The short-term efficacy of 3-month LA in the treatment of CPP in girls is similar to that of 1-month LA.The 3-month dosage form LA is a safe,effective,and economical method for the treatment of CPP in girls. 展开更多
关键词 Central precocious puberty GIRL Lepraline acetate gonadotropin-releasing hormone AGONIST
下载PDF
野生鲇鱼生长激素分泌的季节变化及其神经内分泌调控 被引量:16
15
作者 温海深 林浩然 +2 位作者 肖东 A.O.L.WONG E.K.Y.LEE 《动物学报》 SCIE CAS CSCD 北大核心 2002年第2期213-220,共8页
采用离体垂体碎片灌流孵育系统 ,将处于性腺退化期野生鲇鱼垂体切成约 1mm3 的碎片 ,用M 199冲洗之后放入灌流柱的两层Cytodex -Ⅲ微载体之间 (温度为 19± 1℃ )。每 5分钟收集一管灌流液 ,- 2 5℃贮存待测GH。采用鲤鱼GH放射免疫... 采用离体垂体碎片灌流孵育系统 ,将处于性腺退化期野生鲇鱼垂体切成约 1mm3 的碎片 ,用M 199冲洗之后放入灌流柱的两层Cytodex -Ⅲ微载体之间 (温度为 19± 1℃ )。每 5分钟收集一管灌流液 ,- 2 5℃贮存待测GH。采用鲤鱼GH放射免疫测定方法 (cGHRIA)测定鲇鱼垂体碎片灌流液以及血清和垂体中的GH含量。结果表明 :促黄体素释放激素类似物 [desGly10 (D Ala6)LHRHethylamide ,LHRH A]不能显著刺激离体垂体碎片基础GH分泌 ,注射LHRH A后不能显著提高血清基础GH水平 ;注射DA能显著提高鲇鱼血清基础GH水平 ,APO能以剂量依赖方式显著刺激垂体碎片基础GH分泌。雌、雄鲇鱼血清GH水平在 6月达到峰值 ,垂体GH水平在 3月和 7月份各出现一个峰值 ,各个季节雌鱼垂体和血清GH水平均显著高于雄鱼。鲇鱼血清和垂体GH水平与生殖周期有密切联系。 展开更多
关键词 野生鲇鱼 生长激素 分泌 季节变化 神经内分泌 调控
下载PDF
子宫内膜异位症术后GnRH-a治疗与黑升麻制剂的使用 被引量:7
16
作者 陈继明 吴洁 +2 位作者 浦丹华 高红艳 李沁 《中国妇幼健康研究》 2014年第2期344-347,共4页
子宫内膜异位症(EMS)是临床上最常见的妇科疾病之一,术后的复发问题一直困扰着临床医师。促性腺激素释放激素激动剂(GnRH-a)的使用对于降低EMS术后的复发具有十分重要的作用,目前已成为临床上最为常用的预防EMS复发的方法。但是,GnRH-a... 子宫内膜异位症(EMS)是临床上最常见的妇科疾病之一,术后的复发问题一直困扰着临床医师。促性腺激素释放激素激动剂(GnRH-a)的使用对于降低EMS术后的复发具有十分重要的作用,目前已成为临床上最为常用的预防EMS复发的方法。但是,GnRH-a使用后引发的围绝经期症状严重影响患者的生活质量,部分患者因此而终止治疗。激素反向添加治疗虽然很好的解决了围绝经期症状,但是激素的长期使用可能导致激素依赖性疾病的风险。作为一种植物提取物,黑升麻制剂能否较好的拮抗GnRH-a所致类围绝经期症状,而且又能避免激素反向添加治疗的风险,目前尚不明确。该文主要围绕EMS术后GnRH-a治疗的必要性及其存在的问题,黑升麻制剂的作用机制与功能,黑升麻用于缓解EMS患者术后使用GnRH-a治疗出现的类围绝经期症状的可能性及可能存在的问题进行概述。 展开更多
关键词 子宫内膜异位症 促性腺激素释放激素激动剂 围绝经期症状 反向添加治疗 黑升麻制剂 ENDOMETRIOSIS (EMS) gonadotropin-releasing hormone AGONIST (GnRH-a)
下载PDF
小剂量雌激素联合促性腺激素释放素类似物治疗儿童特发性中枢性性早熟 被引量:11
17
作者 赵岫 张琴 高晓杰 《新乡医学院学报》 CAS 2011年第4期454-457,共4页
目的观察小剂量雌激素联合促性腺激素释放素类似物(GnRHa)治疗特发性中枢性性早熟(ICPP)的效果。方法 45例ICPP伴生长减速患儿分为3组:雌激素联合GnRHa治疗组、重组人生长激素(rhGH)联合GnRHa治疗组、单纯GnRHa治疗组,每组15例。分别于... 目的观察小剂量雌激素联合促性腺激素释放素类似物(GnRHa)治疗特发性中枢性性早熟(ICPP)的效果。方法 45例ICPP伴生长减速患儿分为3组:雌激素联合GnRHa治疗组、重组人生长激素(rhGH)联合GnRHa治疗组、单纯GnRHa治疗组,每组15例。分别于治疗前和治疗6个月后观察3组患儿骨龄(BA)、年生长速率(GV)、体质量、身高(Ht)、骨龄身高(Htba)、成年预测身高(PAH)、血脂、血糖、胰岛素、甲状腺功能、雌二醇(E2)、睾酮(T)、泌乳素(PRL)、血胰岛素样生长因子1(IGF-1)、乳房及子宫卵巢B超等的变化;另行GnRH激发试验监测促黄体生成素(LH)和促卵泡雌激素(FSH)水平。结果 3组患儿治疗前Ht、Htba、骨龄/年龄(BA/CA)、PAH、GV、体质量、IGF-1比较差别均无统计学意义(P>0.05)。治疗6个月后,雌激素联合GnRHa治疗组患儿GV、Ht、PAH明显高于治疗前(P<0.05),rhGH联合GnRHa治疗组患儿GV、Ht、PAH、IGF-1明显高于治疗前(P<0.05);且雌激素联合GnRHa治疗组和rhGH联合GnRHa治疗组患儿GV、Ht、PAH明显高于单纯GnRHa治疗组(P<0.05);rhGH联合GnRHa治疗组患儿IGF-1明显高于雌激素联合GnRHa治疗组和单纯GnRHa治疗组(P<0.05)。3组治疗前后E2、T、PRL、乳房及子宫和卵巢B超结果均无明显变化,GnRH激发试验LH、FSH和LH/FSH亦无明显变化(P>0.05)。结论小剂量雌激素联合GnRHa治疗ICPP,能在不加速BA的情况下有效地提高生长速率,且雌激素价格便宜,患者依从性好。 展开更多
关键词 促性腺激素释放素类似物 雌激素 生长激素 性早熟
下载PDF
半胱胺盐酸盐和LHRH-A对黄鳍鲷IGF-Ⅰ基因表达和生长的影响 被引量:11
18
作者 石和荣 张勇 +3 位作者 张为民 刘晓春 柯浩 林浩然 《动物学报》 SCIE CAS CSCD 北大核心 2005年第1期108-116,共9页
本文以黄鳍鲷 (Sparuslatus)为研究对象 ,利用GeneRaceTM 技术 ,从其肝组织中克隆出类胰岛素生长因子 (IGF Ⅰ )cDNA ,并应用半定量RT PCR方法研究了半胱胺盐酸盐 (Cysteaminehydrochloride)和LHRH A对其肝组织IGF Ⅰ基因表达的影响。... 本文以黄鳍鲷 (Sparuslatus)为研究对象 ,利用GeneRaceTM 技术 ,从其肝组织中克隆出类胰岛素生长因子 (IGF Ⅰ )cDNA ,并应用半定量RT PCR方法研究了半胱胺盐酸盐 (Cysteaminehydrochloride)和LHRH A对其肝组织IGF Ⅰ基因表达的影响。黄鳍鲷IGF ⅠcDNA全长为 84 0bp ,编码 185aa多肽 ;序列分析表明 ,黄鳍鲷IGF Ⅰ基因编码的氨基酸序列与金鱼的同源性为 75 8% ,与牙鲆的同源性为 86 5 % ,与同属鲷科的黑鲷同源性高达 10 0 % ,证明鱼类类胰岛素生长因子是非常保守的 ,E区域分析结果表明黄鳍鲷IGF Ⅰ属Ea 4型。在饲料中投喂CSH、LHRH A等添加剂 ,实验组黄鳍鲷鱼种的相对生长率、垂体GH含量、肝脏IGF ⅠmRNA水平均显著高于对照组。以上结果提示 :CSH、LHRH A能促进黄鳍鲷生长激素的合成和IGF Ⅰ基因的表达 。 展开更多
关键词 IGF-Ⅰ LHRH CSH 肝组织 基因表达 对照组 影响 黄鳍鲷 半胱胺 生长
下载PDF
促黄体素释放激素类似物和多巴胺对鲤鱼幼鱼和性成熟雌鱼生长激素分泌的作用 被引量:11
19
作者 王黎 林浩然 《动物学报》 SCIE CAS CSCD 1997年第3期303-308,共6页
以性腺未发育的5~6月龄幼鲤和1龄性成熟雌鲤为材料,研究年龄对促黄体素释放激素类似物和多巴胺能药物刺激的鲤鱼GH分泌的影响。结果表明:5~6月龄幼鱼血清基础GH水平明显低于1龄性成熟鱼;5~6月龄幼鱼对LHRHA、D... 以性腺未发育的5~6月龄幼鲤和1龄性成熟雌鲤为材料,研究年龄对促黄体素释放激素类似物和多巴胺能药物刺激的鲤鱼GH分泌的影响。结果表明:5~6月龄幼鱼血清基础GH水平明显低于1龄性成熟鱼;5~6月龄幼鱼对LHRHA、DA和APO刺激的GH分泌的反应性也明显低于1龄性成熟鱼;DA和APO在5~6月龄幼鱼和1龄性成熟鱼都不能增强LHRHA对GH分泌的刺激作用;DOM不影响5~6月龄幼鱼和1龄性成熟鱼的血清GH水平。 展开更多
关键词 鲤鱼 生长激素 促黄体素 释放激素类似物 多巴胺
下载PDF
松节油合成保幼激素类似物的研究进展 被引量:11
20
作者 王宗德 周永红 宋湛谦 《林产化学与工业》 EI CAS CSCD 2002年第3期75-78,共4页
对松节油合成保幼激素类似物 (JHA)的研究进展进行了综述。以松节油的主要组分α 蒎烯为原料 ,所合成JHA的结构可以分为 3类 ,即四元环结构的JHA、五元环结构的JHA和具有α 蒎烯基本结构的JHA。研究的现状是合成工作多 ,而实际应用少。... 对松节油合成保幼激素类似物 (JHA)的研究进展进行了综述。以松节油的主要组分α 蒎烯为原料 ,所合成JHA的结构可以分为 3类 ,即四元环结构的JHA、五元环结构的JHA和具有α 蒎烯基本结构的JHA。研究的现状是合成工作多 ,而实际应用少。因带有醚类基团的JHA具有较高的保幼激素活性 ,故建议加强α 蒎烯合成醚类JHA及其应用开发的研究。同时 ,建议利用与α 蒎烯结构相近的 β 蒎烯合成JHA。 展开更多
关键词 合成 研究进展 松节油 保幼激素类似物 杀虫剂 Α-蒎烯
下载PDF
上一页 1 2 6 下一页 到第
使用帮助 返回顶部